Ms. Quish is a Managing Director based in Menlo Park for the Fortress Credit Funds Business where she heads Asset Management for Fortress’s Intellectual Property Finance Group. In this role, she provides counsel and advice to portfolio companies that are engaged in monetization efforts. Ms. Quish has 20 years of experience assessing and monetizing patent assets. Prior to joining Fortress in 2018, Ms. Quish held the position of Vice President of Patent Strategy and M&A at Rovi Corporation, a TiVo Company where she was responsible for leading patent acquisitions and patent-heavy corporate acquisitions as well as designing and implementing IP monetization strategies. Prior to joining Rovi, Ms. Quish was a Member of Mintz Levin’s patent litigation practice where she spent the majority of her time representing patent owners in licensing and litigation matters including litigation in U.S. district courts and the International Trade Commission. Ms. Quish has been recognized by Intellectual Asset Magazine on a number of occasions, including being identified as one of the World’s Global Leaders in IP and the World’s Leading IP Strategists, where individuals are recognized for their experience related to creating and enforcing critical patent rights to help maximize the value of IP portfolios. In the past, Ms. Quish was also identified as one of the 40 world “Elite Dealmakers” and 1 of 10 “IP Personalities” by the same publication. Ms. Quish earned her J.D. from the University of Michigan Law School and her B.A. with High Honors from Middlebury College.
From the Courthouse Steps: Hikma v. Amarin
Adam Mossoff, Wesley Weeks
In Hikma Pharmaceuticals USA v. Amarin Pharma, the Supreme Court unanimously held that, to plausibly allege induced...
Litigation Transparency Act of 2025: Patents, Policy, and Legal Ethics
Kacie Donovan, Kristen Osenga, Courtney Quish, Jonathan Stroud, Paul Brian Taylor
Prompted by the reintroduction of federal Litigation Transparency Act legislation, this panel will address a...
Does Jarkesy Doom the Preserve Access to Affordable Generics and Biosimilars Act?
Matthew S. Hellman, William M. Jay, Emily Michiko Morris, Brian Pandya, Matthew D. Rowen
Reducing the cost of prescription drugs has been a bipartisan priority for years. One recent...
Patent Owners in the Soup... No Injunction for You!
Jonathan Barnett, Thomas F. Cotter, Jeffrey E. Depp, Paul Redmond Michel
Some Intellectual Property experts contend that American patent reliability has been in decline for 20...
What is the Role of the ITC in Patent Cases?
Jorge L. Contreras, Michael Doane, Michael K. Friedland, F. Scott Kieff
The U.S. International Trade Commission (ITC), long a favored forum for patent infringement disputes, has...
The Injunction Function: Is IP Law Promoting Markets for Innovators and Creators?
John W. Holcomb, Ryan T. Holte, Kristen Osenga, Laurie Self, Laura Sheridan
In patent and copyright law, injunctions are now a subject of significant policy debate. Innovators...
Amgen Inc. v. Sanofi - Post-Argument SCOTUScast
Robert J. Rando
On November 4, 2022, the Supreme Court granted cert in Amgen Inc. v. Sanofi, a...
The EU’s Proposed Regulations of SEP Licensing and Litigation: A Solution or Setback for the Global Innovation Economy?
Jorge L. Contreras, Adam Mossoff, Elisabeth Opie, Ur?ka Petrov?i?
The European Union is considering adopting a wide-ranging regulatory regime for the licensing and litigation...
A Response to: Ten Years On: The America Invents Act and the role of the Patent Trial and Appeal Board in resolving patent disputes
Thomas D. Grant, F. Scott Kieff, Paul Redmond Michel
Join us on July 27 to hear three experts give a response to our April...
Ten Years On: The America Invents Act and the role of the Patent Trial and Appeal Board in resolving patent disputes
Joseph Matal, Paul Brian Taylor, Bob Goodlatte
On September 16, 2011, President Obama signed the American Invents Act (AIA) into law. The...